Key Highlights

  • Ginkgo Bioworks shares are trading down 7.41% today, sinking toward multi-week lows.
  • TD Cowen downgraded the stock to Hold from Buy and cut its price target to $9 from $12.
  • Second-quarter revenue fell 19% year-over-year to $20.2 million, though the company narrowed its full-year net loss guidance.
  • The move stands in contrast to gains posted by peers Vir Biotechnology and Halozyme this week.

Why Is Ginkgo Bioworks Stock Falling Today?

Ginkgo Bioworks (NYSE:DNA) shares are sinking today after TD Cowen downgraded the stock to Hold from Buy, cutting its price target to $9 from $12, citing uncertainty around the company's near-term growth drivers. The downgrade follows second-quarter results in which revenue fell 19% year-over-year to $20.2 million, while net loss from continuing operations widened to $57 million from $25 million a year earlier, partly due to $14 million in excess lease costs.

Ginkgo Bioworks is a Boston-based biotechnology company that has built a horizontal platform for cell engineering and biosecurity, operating through its Cell Engineering and Biosecurity segments to design, optimize, and scale engineered organisms using tools spanning genomics, AI models, and automated foundry infrastructure.

Relative Weakness Against Sector Peers

Today's decline highlights Ginkgo's relative underperformance against the broader healthcare sector, which is trading near multi-week highs, with peers Vir Biotechnology (NASDAQ:VIR) and Halozyme (NASDAQ:HALO) both posting strong beats and guidance updates this week. The company did reaffirm full-year 2026 cash burn guidance of $125 to $150 million and reported $302 million in cash and cash equivalents plus $87 million in restricted cash, alongside strategic highlights including expansion of its Nebula autonomous lab in Boston and new biosecurity partnerships.

Despite these operational updates, the near-term revenue decline and widened losses appear to be outweighing the longer-term strategic narrative in today's trading.

Conclusion

Ginkgo Bioworks shares are falling today following an analyst downgrade tied to concerns about near-term growth, compounded by second-quarter results showing declining revenue and a widened net loss. The stock's weakness stands in contrast to broader strength across the healthcare sector this week.

This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.